Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
| ▸ | SLC8A1 | P32418 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.31 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | PHGDH | O43175 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23051947 | 1.00 | FAAH (0.34) | FAAHSLC8A1POLBSMN1; SMN2HSP90AA1 | |
| SCHEMBL28721016 | 0.94 | CNR2 (0.34) | POLBHSP90AA1MMECNR1CNR2 | |
| SCHEMBL23051965 | 0.94 | CNR2 (0.34) | POLBHSP90AA1MMECNR1CNR2 | |
| SCHEMBL23041388 | 0.92 | MME (0.36) | MMEMMEL1PHGDH | |
| SCHEMBL23041498 | 0.92 | MME (0.36) | MMEMMEL1PHGDH | |
| SCHEMBL23041497 | 0.92 | MME (0.36) | MMEMMEL1PHGDH | |
| SCHEMBL23041387 | 0.92 | MME (0.36) | MMEMMEL1PHGDH | |
| SCHEMBL23052223 | 0.90 | FAAH (0.34) | FAAHSLC8A1POLBSMN1; SMN2HSP90AA1 | |
| SCHEMBL29452755 | 0.90 | FAAH (0.34) | FAAHSLC8A1POLBSMN1; SMN2HSP90AA1 | |
| SCHEMBL23051964 | 0.89 | MME (0.34) | MMEMMEL1PHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220306617-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2022-09-29 | — | — | US | claimed |
| EP-4021572-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2022-07-06 | — | — | EP | claimed |
| US-20220306617-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2022-09-29 | — | — | US | disclosed |
| EP-4021572-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| CN-114341132-A | Substituted 1, 3-phenylheteroaryl derivatives and their use in the treatment of diseases | 诺华股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2021038426-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306617-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | CFTR, TMEM161A, TMEM164 | FAAH 3187/4885SLC8A1 430/4885POLB 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.